Compass Therapeutics Inc. (CMPX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $139.35M
Last updated: Nov 17, 2026 at 4:38 PM ET
Compass Therapeutics Inc. (CMPX) Statistics
Compass Therapeutics (CMPX) has a market cap of $139.35M and an enterprise value of $97.88M. Its share count is up 10.67% from a year earlier. It holds $41.47M more cash than debt, 29.76% of its market cap.
Total Valuation
Enterprise value is 29.76% below the market cap, as cash exceeds debt.
| Market Cap | $139.35M |
|---|---|
| Enterprise Value | $97.88M |
| Latest price (Nov 17, 2026) | $0.61 |
Key Dates
The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 87.44% over 52 weeks and trades 42.99% below its 50-day average.
| Beta (1Y) | 1.75 |
|---|---|
| 52-Week Change | -87.44% |
| 1-Month Change | -27.34% |
| 3-Month Change | -75.54% |
| 6-Month Change | -66.48% |
| 5-Year Change | -73.96% |
| Total Return (1Y) | -87.44% |
| Total Return (3Y CAGR) | -27.46% |
| Total Return (5Y CAGR) | -30.99% |
| Max Drawdown (1Y) | -90.93% |
| Max Drawdown (3Y) | -90.93% |
| Sharpe Ratio (1Y) | -1.64 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $1.07 |
| 200-Day Average | $2.87 |
| 52-Week Range | $0.66 to $6.88 |
| RSI (14 Days) | 27.1 |
| Average Volume (20 Days) | 2.07M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.79x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.79x |
|---|---|
| Quick Ratio | 6.79x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -60.57% over the last 12 months, against a 5-year average of -36.42%.
| Return on Equity (ROE) | -60.57% |
|---|---|
| Return on Assets (ROA) | -49.49% |
| Return on Capital Employed (ROCE) | -57.52% |
| ROE (5Y Average) | -36.42% |
| ROA (5Y Average) | -33.13% |
| ROIC (5Y Average) | -26.69% |
Scores
CMPX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$370.00K |
| Operating Income | -$94.07M |
| Pretax Income | -$86.36M |
| Net Income | -$86.36M |
| EBIT | -$86.36M |
| Reported EPS (TTM) | -$0.47 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 81.70% of the $174.50M in total assets.
| Cash and Equivalents | $41.47M |
|---|---|
| Total Debt | $0 |
| Net Cash | $41.47M |
| Net Cash Per Share | $0.22 |
| Working Capital | $141.13M |
| Shareholder Equity | $142.57M |
| Book Value Per Share | $0.76 |
| Total Assets | $174.50M |
| Total Liabilities | $31.93M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $364.00K of capital spending, operating cash flow left -$61.94M of free cash flow.
| Operating Cash Flow | -$61.58M |
|---|---|
| Capital Expenditures | $364.00K |
| Free Cash Flow | -$61.94M |
| FCF Per Share | -$0.34 |
| Depreciation and Amortization | $1.67M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -4.34% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -4.34% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CMPX
What is CMPX's market cap?
Compass Therapeutics has a market cap of $139.35M. Its enterprise value, which adds debt and subtracts cash, is $97.88M.
How many shares of CMPX are outstanding?
Compass Therapeutics has 186.80M shares outstanding. The count is up 10.67% from a year earlier.
Does CMPX pay a dividend?
No. Compass Therapeutics does not pay a dividend.
How much debt does CMPX have?
Compass Therapeutics has $0 of total debt and $41.47M of cash and equivalents, a net cash position of $41.47M.
CMPX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors